Page 1216 - Basic _ Clinical Pharmacology ( PDFDrive )

1202 Index

Compound optimization, 13 preparations of, 730t–731t, 732 clinical pharmacology of, 709–714
Concentration-dependent killing, 828, 910 progestin-only contraception, 736 contraindications and cautions in, 713
Concentration-effect curves, receptor bind- types of, 732 diagnostic uses in, 711
ing of agonists on, 21–22, 22f Contractility, cardiac, 216, 216f drug selection and dosage in, 713–714
Concentration measurements Controlled clinical trial, 2 fetal lung maturation, 711
clearance in, 53 Controlled ovarian stimulation mineralocorticoids
dosing history in, 53 GnRH for, 677 aldosterone, 714–715
initial predictions in, 54 gonadotropins for, 674, 675f deoxycorticosterone, 714–715
revising individual estimates of, 54 Controlled substances, 1153, 1153t fludrocortisone, 715
timing of samples for measurement of, Conus, 370b nonadrenal disorders, 711–712, 712t
53–54 Conversions, for prescriptions, 1148 pharmacodynamics of, 709, 709t
volume of distribution in, 54 Converting enzyme, in angiotensin pharmacokinetics of, 706f, 709, 709t
on pharmacologic effects, 20, 21–26. biosynthesis, 303 preparations available, 718t
See also Dose, on pharmacologic Convulsions, neuromuscular blockers for, 484 toxicity in, 712–713
effects Coplanar biphenyls, 1015 Corticotropin, 703
Conductance, potassium on, 231b Copy number variations (CNVs), 75t Corticotropin-releasing hormone (CRH),
Conduction, heart, 228, 229f Coral snake antivenom, 1181t 669, 669t
Conflicts of interest, 18 Coral snake hyperimmune globulin, 991 Cortisol, 704–709, 718t. See also Glucocor-
Confounding factors, 14 Coronary artery disease (CAD) ticoids, naturally occurring
Congenital adrenal hyperplasia, 710 angina pectoris from, 194 Cortisone, 709t. See also Corticosteroids,
Conivaptan, 308, 682, 684t case study of, 194, 211 synthetic
diuresis using, 268–269, 273t with hyperlipidemia, 194, 211 Cost, prescription, 1154
heart failure treated with, 224 hypertension and, anesthesia with, 440 Cotransmitters, 93
on vasoactive peptides, 317t myxedema and, 697 autonomic, 93
Conjugates, drug, 63, 64f, 64t treatment of, 207 in cholinergic and adrenergic nerves,
Conn’s syndrome, 266 Coronary blood flow, 195 97–98
Consciousness, in anesthesia, 447b Coronary heart disease, 401 Coupling
Conscious sedation, 441b Coronary steal, 206b definition of, 22
Constipation, opioid-induced, 562 Corticosteroids receptor-effector, and spare receptors,
Constitutive activity, 5 antiemetic properties of, 1105 22f, 22–23
Contact hypersensitivity, 983 asthma treated with, 354–355, 359, Covalent bonds, 3–4
Context-sensitive half-time, 451, 451f 362t, 363t COX-1, 323, 324f
Continuing medical education (CME), 18 on eicosanoid synthesis, 332 COX-2, 263, 323, 324f
Continuous subcutaneous insulin infusion in elderly, 1064 COX inhibitors
(CSII) devices, 756–757 gout treated with, 663 Bartter’s syndrome treated with, 335
Contraception, hormonal, 732–737 immunosuppressive uses of, 985t, ductus arteriosus delayed closure treated
adverse effects of, 734–736 985–986 with, 335
beneficial effects of, 737 inhaled (aerosol), 354–355, 359, 362t, COX-2 inhibitors
clinical uses of, 734 363t adverse effects of, 643
contraindications and cautions with, 736 rheumatoid arthritis treated with, azapropazone, 649
emergency, OTC, 1125t 658–659 carprofen, 649
mechanism of action of, 732 topical, 1079–1081, 1080t, 1081t celecoxib, 645t, 647
monophasic, biphasic, and triphasic, 732 adverse effects of, 1081 diclofenac, 644f, 645t, 647
pharmacologic effects of, 732–734 chemistry and pharmacokinetics of, diflunisal, 645t, 647
physiologic effects of, 728t, 729, 729f, 1080t, 1080–1081 etodolac, 645t, 647
730t–731t dermatologic, 1079–1082, 1080t, flurbiprofen, 644f, 645t, 647
blood, 733 1081t ibuprofen, 644f, 645t, 647–648
breast, 733 Corticosteroids, synthetic indomethacin, 644f, 645t, 648
carbohydrate metabolism, 733 adrenal androgens, 715 ketoprofen, 645t, 648
cardiovascular system, 734 adrenocortical hypo- and hyperfunction meclofenamate, 649
CNS, 733 uses of meloxicam, 645t, 647
endocrine functions, 733 aldosteronism, 710–711 nabumetone, 644f, 645t, 648
lipid metabolism, 733 Chrousos syndrome, 710 naproxen, 645t, 648
liver, 733 congenital adrenal hyperplasia, 710 nonselective, 647–648
ovary, 732–733 Cushing’s syndrome, 710 oxaprozin, 645t, 648
skin, 734 adrenocortical insufficiency uses of piroxicam, 644f, 645t, 648
uterus, 733 acute, 710 selective, 645t, 645–647
postcoital contraceptives, 736t, 736–737 chronic (Addison’s disease), 709–710 sulindac, 645t, 648–649